UNITED THERAPEUTICS Corp
UTHRUS売上高
$3.2B
百万USD
営業利益
$1.5B
百万USD
純利益
$1.3B
百万USD
ROE
18.8%
最新FY
EPS
$27.86
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $379M | $28M | $0.61 |
| FY2021 | Q2 | $447M | $173M | $3.65 |
| FY2021 | Q3 | $445M | $163M | $3.42 |
| FY2021 | FY | $1.7B | - | $10.06 |
| FY2022 | Q1 | $462M | $240M | $5.03 |
| FY2022 | Q2 | $467M | $116M | $2.41 |
| FY2022 | Q3 | $516M | $239M | $4.91 |
| FY2022 | FY | $1.9B | - | $15.00 |
| FY2023 | Q1 | $507M | $241M | $4.86 |
| FY2023 | Q2 | $597M | $259M | $5.24 |
| FY2023 | Q3 | $609M | $268M | $5.38 |
| FY2023 | FY | $2.3B | $985M | $19.81 |
| FY2024 | Q1 | $678M | $307M | $6.17 |
| FY2024 | Q2 | $715M | $278M | $5.85 |
| FY2024 | Q3 | $749M | $309M | $6.39 |
| FY2024 | FY | $2.9B | $1.2B | $24.64 |
| FY2025 | Q1 | $794M | $322M | $6.63 |
| FY2025 | Q2 | $799M | $310M | $6.41 |
| FY2025 | Q3 | $800M | $339M | $7.16 |
| FY2025 | FY | $3.2B | $1.3B | $27.86 |
| FY2026 | Q1 | $782M | $275M | $5.82 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $1.6B | $1.4B | $1.5B | $1.7B | $1.9B | $2.3B | $2.9B | $3.2B |
| 営業利益 | $1.1B | $815M | $805M | $-188M | $594M | $556M | $980M | $1.2B | $1.4B | $1.5B |
| 純利益 | - | - | - | - | - | - | - | $985M | $1.2B | $1.3B |
| 総資産 | $2.3B | $2.9B | $3.4B | $3.9B | $4.6B | $5.2B | $6.0B | $7.2B | $7.4B | $7.9B |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $1.9B | $2.1B | $2.8B | $2.8B | $3.4B | $4.0B | $4.8B | $6.0B | $6.4B | $7.1B |
| 営業CF | - | $474M | $778M | $-207M | $756M | $598M | $803M | $978M | $1.3B | $1.6B |
| EPS | $15.25 | $9.31 | $13.39 | $-2.39 | $11.54 | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| BPS | $41.18 | $48.61 | $63.78 | $63.36 | $76.22 | $87.72 | $103.60 | $127.18 | $143.48 | $161.91 |
| ROE | - | - | - | - | - | - | - | 16.5% | 18.5% | 18.8% |